COPD

New findings from the phase 3 trial show budesonide/ glycopyrrolate/ formoterol fumarate significantly reduces exacerbations among patients with no exacerbation history, compared to dual therapies.

From medical marijuana to vape devices, there seems to be a divide in defining what's legal for use, and what's actually beneficial for users.

How the LAMA therapy manages one of the integral facets of COPD care.

While one disease is benefitting from advancing digital screening measures, the other has a standard therapy which could provide benefit to both.

A new study finds the months of January-March are most burdened with COPD exacerbation-based hospitalizations, mortality, and hospital costs.

How should physicians navigate the public belief that vaping is less harmful than cigarette smoking?

A new study shows the underutilized test could reveal an additional 9% of asthma diagnoses and potentially 8% of asthma-COPD overlap syndrome cases.

How the aclidinium bromide trial brings novel perspective to COPD care.

The chronic respiratory disease is often under-diagnosed in female patients.

New ASCENT-COPD data show the therapy's benefit in reducing cardiovascular events among high-risk patients, along with significant exacerbation reduction.

The fixed-dose therapy was shown to reduce exacerbations, regardless of patient history, among those with increased cardiovascular risk.

What the introduction of aclidinium/formoterol could mean for patients with COPD.

The approved label update now indicates the therapy delays disease progression when used in combination with an approved oral background PAH therapy.

The most recent CDC data, presented at CHEST 2019, show nearly 1500 patients have reported an associated lung injury, and 33 have died.

A new study shows adult e-cigarette use in the US was steadily dropping since 2014— before spiking in 2018 among adults aged 18-24 years.

Trelegy Ellipta could become the first triple-combination, single-inhaler therapy approved for the treatment of both asthma and COPD.

An expert with the American Lung Association will lead discussion on one of the greatest drivers of death in the US.

The investigative ICS/LAMA/LABA inhaler therapy reported positive findings from its phase 3 ETHOS trial in August, though the results were not included in the FDA application.

The 12-year update highlights promising novel therapy classes, and sets disparities between pediatric and adult chronic cough treatment.

Results from the TRIMARAN and TRIGGER trials show significant benefits for 2 different doses of the ICS/LABA/LAMA combination.

A new study from ERS showed the technological material common among training athletes could help physicians monitor patients with COPD.

A new study from the ERS International Congress shows a trio of air pollutants are associated with significant increases in all-cause infant mortality in the UK.

A new study shows that approximately one-quarter of adults aged 18-34 years old with a medical condition have used marijuna in the past month.

A six-month regimen of the oral therapy showed patients with out-of-proportion PH improved their six-minute walking test scores.

Obstructive sleep apnea has been consistently underdiagnosed in US populations. Are screening methods enough?